Is an Existing English Label Always Acceptable in the Target Country? | FAQ

No. An existing English label is not necessarily acceptable in the target country. Some countries require the local language; others require the manufacturer, local authorized representative, importer, registration certificate number, warnings, or specific symbols to be displayed simultaneously. Even where English is accepted, there may be specific requirements for label items, format, UDI placement, instructions for use content, and product claims. Label localization should be consistent with the registration dossier, actual packaging, import clearance, and post-market traceability; otherwise, it may affect review, import, or post-market compliance.

FAQ: Is an Existing English Label Always Acceptable in the Target Country?

Published: 2026-07-08 09:00 | Updated: 2026-07-08 09:00

This FAQ addresses priority questions that companies need to assess in medical device international registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Assessment Logic
• Documentation Priorities
• Common Misconceptions
• AIMEILI Perspective
• Continue Reading
• Applicability Boundaries

Key Summary

An existing English label is not necessarily acceptable in the target country. Some countries require local language; others require simultaneous display of the manufacturer, local representative, importer, registration certificate number, warnings, or specific symbols. Even when English is accepted, requirements may cover label items, format, UDI placement, instructions for use content, and product claims. Label localization should be aligned with the registration dossier, actual packaging, import clearance, and post-market traceability; otherwise, it may affect review, import, or post-market compliance.

Assessment Logic

Companies should first assess the target market, registration pathway, commercial launch plan, and current documentation status in the same decision matrix. Without an initial pathway assessment, subsequent work on local authorized representatives, labeling, testing, clinical evidence, or certificate maintenance may require repeated rework.

Documentation Priorities

Documentation preparation should focus on whether the product description, intended use, model and specifications, risk management, performance verification, clinical or evaluation evidence, labels and instructions for use, quality system evidence, authorization documents, and post-market maintenance arrangements are consistent with one another.

Common Misconceptions

A common misconception is to treat the local authorized representative as an ordinary commercial contact while ignoring its responsibilities for receiving regulatory notifications, maintaining certificates, supporting adverse event handling, and transferring documents. If the representative arrangement is unclear, it may later affect channel changes and market control.

AIMEILI Perspective

AIMEILI recommends that companies assess this question at project initiation rather than handling it temporarily before submission. A more robust approach is to first complete product classification, documentation gap analysis, target country prioritization, local responsible entity arrangements, and post-market maintenance planning, and then form an executable registration plan.

Continue Reading

• Previous: When are labels, instructions for use, and UDI usually prepared?
• Next: Do all medical devices require clinical trials for overseas registration?

Recommended Reading

• How should the medical device registration document checklist for Indonesia be prepared?
• How is the Singapore HSA medical device registration process conducted?
• What documents are required for medical device import registration in Vietnam?
• How should a local authorized representative be selected for medical device registration in the Middle East?
• Malaysia MDA medical device registration document checklist?
• Saudi SFDA medical device registration document checklist?

Back to FAQ Center | News and Insights | Contact AIMEILI

Content Review and Applicability Boundaries

Author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Compiled by the AIMEILI Regulatory Editorial Team based on public regulatory materials and registration practice.

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as auxiliary references.

Applicability boundaries: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.